AGL 40.22 Increased By ▲ 0.21 (0.52%)
AIRLINK 127.06 Decreased By ▼ -0.93 (-0.73%)
BOP 6.61 Increased By ▲ 0.01 (0.15%)
CNERGY 4.51 Decreased By ▼ -0.09 (-1.96%)
DCL 8.54 Increased By ▲ 0.06 (0.71%)
DFML 41.65 Increased By ▲ 0.17 (0.41%)
DGKC 87.03 Increased By ▲ 0.45 (0.52%)
FCCL 32.65 Increased By ▲ 0.51 (1.59%)
FFBL 65.35 Decreased By ▼ -0.07 (-0.11%)
FFL 10.23 Decreased By ▼ -0.02 (-0.2%)
HUBC 109.60 Decreased By ▼ -0.89 (-0.81%)
HUMNL 14.58 Decreased By ▼ -0.17 (-1.15%)
KEL 5.13 No Change ▼ 0.00 (0%)
KOSM 7.62 Increased By ▲ 0.50 (7.02%)
MLCF 41.65 No Change ▼ 0.00 (0%)
NBP 59.65 Decreased By ▼ -0.44 (-0.73%)
OGDC 194.20 Decreased By ▼ -0.49 (-0.25%)
PAEL 28.21 Increased By ▲ 0.26 (0.93%)
PIBTL 7.88 Decreased By ▼ -0.12 (-1.5%)
PPL 152.35 Increased By ▲ 1.18 (0.78%)
PRL 26.55 Decreased By ▼ -0.33 (-1.23%)
PTC 16.05 Increased By ▲ 0.05 (0.31%)
SEARL 81.75 Increased By ▲ 3.55 (4.54%)
TELE 7.48 Increased By ▲ 0.09 (1.22%)
TOMCL 35.45 Decreased By ▼ -0.22 (-0.62%)
TPLP 8.25 Increased By ▲ 0.34 (4.3%)
TREET 16.16 Increased By ▲ 0.27 (1.7%)
TRG 52.84 Increased By ▲ 0.08 (0.15%)
UNITY 26.70 Increased By ▲ 0.15 (0.56%)
WTL 1.26 Decreased By ▼ -0.01 (-0.79%)
BR100 9,918 Decreased By -2.1 (-0.02%)
BR30 30,797 Increased By 45.1 (0.15%)
KSE100 93,550 Increased By 325.2 (0.35%)
KSE30 28,985 Increased By 99.8 (0.35%)
Business & Finance

Pfizer lifts sales forecast for COVID-19 vaccine to $26 billion

  • It is expected to make up for more than one-third of Pfizer's full-year sales, with the company in supply talks with several countries for 2022 and beyond.
  • "Based on what we've seen, we believe that a durable demand for our COVID-19 vaccine - similar to that of the flu vaccines - is a likely outcome," Chief Executive Albert Bourla said in his prepared remarks.
Published May 4, 2021

Pfizer Inc on Tuesday forecast $26 billion in COVID-19 vaccine sales this year, a more than 70% jump from its last projection, reflecting new contracts with governments around the world trying to halt the pandemic through rapid vaccination.

The raised goal assumes 1.6 billion doses of vaccine, which is co-developed with BioNTech SE, will be delivered in the year, with the two-shot vaccine emerging as the best-selling product for the US drugmaker in the first quarter.

It is expected to make up for more than one-third of Pfizer's full-year sales, with the company in supply talks with several countries for 2022 and beyond.

"Based on what we've seen, we believe that a durable demand for our COVID-19 vaccine - similar to that of the flu vaccines - is a likely outcome," Chief Executive Albert Bourla said in his prepared remarks.

Cost and gross profit from the vaccine are split 50-50 between Pfizer and BioNTech. The two drugmakers had said they aim to produce up to 2.5 billion doses this year, of which 900 million doses have not been included in Pfizer's forecast.

If it sells that number of doses, the vaccine sales in 2021 could be at least 50% higher than the projected $26 billion.

The company has said it expects to profit from the vaccine, while some drugmakers including Johnson & Johnson have said their vaccine will be available on a not-for-profit basis until the end of the pandemic.

Pfizer aims to manufacture at least 3 billion doses of the vaccine next year. It generated $3.5 billion in revenue in the first quarter and beat estimates of $3.28 billion, according to six analysts polled by Refinitiv.

Rival Moderna has forecast $18.4 billion in 2021 sales of its COVID-19 vaccine.

Pfizer said it was using the technology used in the COVID-19 shot known as messenger RNA to develop two flu vaccines that are expected to enter clinical studies in the third quarter.

Shares the company were up 1.4% in premarket trading.

Comments

Comments are closed.